Polar Asset Management Partners Inc. Has $993,000 Stock Holdings in Repligen Co. (NASDAQ:RGEN)

Polar Asset Management Partners Inc. increased its holdings in Repligen Co. (NASDAQ:RGEN) by 76.9% in the fourth quarter, HoldingsChannel reports. The firm owned 6,900 shares of the biotechnology company’s stock after purchasing an additional 3,000 shares during the period. Polar Asset Management Partners Inc.’s holdings in Repligen were worth $993,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of RGEN. Price T Rowe Associates Inc. MD boosted its holdings in Repligen by 11.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,136,054 shares of the biotechnology company’s stock worth $1,027,165,000 after purchasing an additional 743,815 shares in the last quarter. Point72 Asset Management L.P. lifted its position in Repligen by 183.1% during the 4th quarter. Point72 Asset Management L.P. now owns 918,623 shares of the biotechnology company’s stock worth $132,227,000 after acquiring an additional 594,189 shares during the last quarter. Groupama Asset Managment lifted its position in Repligen by 12,321.0% during the 4th quarter. Groupama Asset Managment now owns 403,932 shares of the biotechnology company’s stock worth $58,142,000 after acquiring an additional 400,680 shares during the last quarter. Alyeska Investment Group L.P. acquired a new position in Repligen during the 4th quarter worth $53,428,000. Finally, Raymond James Financial Inc. acquired a new position in Repligen during the 4th quarter worth $52,492,000. 97.64% of the stock is currently owned by institutional investors.

Repligen Stock Performance

NASDAQ:RGEN opened at $122.54 on Wednesday. Repligen Co. has a 12-month low of $102.97 and a 12-month high of $182.52. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The firm has a market capitalization of $6.88 billion, a PE ratio of -240.27, a price-to-earnings-growth ratio of 4.54 and a beta of 1.21. The firm has a 50-day moving average price of $129.41 and a 200 day moving average price of $144.18.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.35 by $0.04. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The firm had revenue of $169.17 million during the quarter, compared to analyst estimates of $163.65 million. During the same quarter in the prior year, the business posted $0.28 earnings per share. The company’s quarterly revenue was up 10.4% compared to the same quarter last year. Research analysts anticipate that Repligen Co. will post 1.72 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have weighed in on RGEN. Evercore ISI began coverage on shares of Repligen in a research report on Tuesday, March 18th. They set an “in-line” rating and a $155.00 target price for the company. Royal Bank of Canada cut their price objective on shares of Repligen from $202.00 to $189.00 and set an “outperform” rating for the company in a research report on Wednesday, April 30th. Wolfe Research raised shares of Repligen from a “peer perform” rating to an “outperform” rating and set a $160.00 price objective for the company in a research report on Tuesday, April 29th. HC Wainwright reaffirmed a “buy” rating and set a $180.00 price objective on shares of Repligen in a research report on Monday, May 5th. Finally, JPMorgan Chase & Co. cut their price objective on shares of Repligen from $200.00 to $190.00 and set an “overweight” rating for the company in a research report on Tuesday, April 29th. Six equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $173.25.

Insider Buying and Selling

In other news, Director Margaret Pax acquired 250 shares of the firm’s stock in a transaction on Monday, March 17th. The shares were purchased at an average cost of $150.69 per share, with a total value of $37,672.50. Following the completion of the purchase, the director now owns 1,043 shares of the company’s stock, valued at $157,169.67. This represents a 31.53% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 1.20% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.